Phathom Pharmaceuticals Aktie
WKN DE: A2PT0F / ISIN: US71722W1071
16.04.2025 23:17:40
|
Phathom Pharmaceuticals Appoints Ted Schroeder To Board Of Directors
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT) Wednesday announced that it has appointed Ted Schroeder to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry.
Schroeder previously served as CEO of Nabriva Therapeutics and co-founded Zavante Therapeutics and Cadence Pharmaceuticals, the latter acquired for USD 1.4 billion. He has held senior roles at Elan, Dura, and Bristol-Myers Squibb and currently serves on the Board of Cidara Therapeutics.
PHAT closed Wednesday's trading at $4.22 down $0.54 or 11.43 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Phathom Pharmaceuticals Inc Registered Shsmehr Nachrichten
30.04.25 |
Ausblick: Phathom Pharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) | |
05.03.25 |
Ausblick: Phathom Pharmaceuticals legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Phathom Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Phathom Pharmaceuticals Inc Registered Shs | 4,12 | 2,49% |
|